Enyo Pharma: Clinical Trials

5 trials sponsored by Enyo Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 2

Follow Enyo Pharma: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Vonafexor low dose, Vonafexor high dose - Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Phase 2TerminatedEnyo Pharma102025-07-012026-04-23
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
Vonafexor - Alport Syndrome
Phase 2CompletedEnyo Pharma262024-08-012026-02-09
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
EYP001a, Entecavir, Pegylated interferon alpha2a - Hepatitis B, Chronic
Phase 2CompletedEnyo Pharma202020-05-252022-08-25
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
EYP001a, Placebo, Nucleotide analogue (Entecavir or Tenofovir Disoproxil) - Hepatitis B, Chronic
Phase 2TerminatedEnyo Pharma262020-05-122022-11-02
Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
Vonafexor, Placebo - Non-alcoholic Steatohepatitis
Phase 2CompletedEnyo Pharma1202019-01-302023-05-06

Conditions studied

Hepatitis B, Chronic (2)  ·  Liver Diseases (1)  ·  Nephritis, Hereditary (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Renal Insufficiency, Chronic (1)

Interventions

entecavir (2)  ·  Tenofovir (1)  ·  peginterferon alfa-2a (1)

Countries

France (2)  ·  Hong Kong (2)  ·  South Korea (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Germany (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Results publications

PMID 36334688, PMID 40938675

NIH funding

2018 (1), 2023 (1)